Please login to the form below

Not currently logged in
Email:
Password:

GSK to produce A (H1N1) vaccine stockpile

Following a WHO announcement of 9,830 reported cases of H1N1 flu; GSK said that it has orders from several governments to create a stockpile of a new vaccine

With the World Health Oganisation (WHO) announcing today that 40 countries have reported 9,830 cases of A (H1N1) flu, GlaxoSmithKline (GSK) said that it has orders from several governments to create a stockpile of a new A (H1N1) vaccine.

GSK expects to manufacture a candidate A (H1N1) adjuvanted influenza vaccine once virus seed is made available by the WHO. First doses of the vaccine are likely to be available four to six months later.

GSK has received interest from several governments aiming to stockpile the vaccine as a precautionary measure, including requests for 60m for the UK; 50m for France; 12.6m for Belgium and 5.3m for Finland.

The new candidate vaccine will require regulatory approval. However, registration should be expedited because in 2008 GSK received a European licence for a pandemic vaccine based on a 'mock-up' dossier. This approval was based on data involving the H5N1 influenza strain.

In clinical studies based on the H5N1 strain, an adjuvanted formulation has been shown to stimulate a higher immune response while using a smaller amount of antigen as compared to a formulation without adjuvant. The adjuvant system helps to increase the number of vaccines doses that can be produced and clinical studies show that it provides potential to offer protection even if the influenza strain changes slightly.

GSK has made substantial investments to expand capacity for its adjuvant system.  

20th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics